Passage Bio (PASG) Competitors $0.30 -0.01 (-4.20%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$0.30 0.00 (-0.33%) As of 05/21/2025 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PASG vs. JMAC, INZY, CRBU, ADAP, GNTA, XCUR, TELO, EPIX, ELUT, and STROShould you be buying Passage Bio stock or one of its competitors? The main competitors of Passage Bio include Maxpro Capital Acquisition (JMAC), Inozyme Pharma (INZY), Caribou Biosciences (CRBU), Adaptimmune Therapeutics (ADAP), Genenta Science (GNTA), Exicure (XCUR), Telomir Pharmaceuticals (TELO), ESSA Pharma (EPIX), Elutia (ELUT), and Sutro Biopharma (STRO). These companies are all part of the "pharmaceutical products" industry. Passage Bio vs. Maxpro Capital Acquisition Inozyme Pharma Caribou Biosciences Adaptimmune Therapeutics Genenta Science Exicure Telomir Pharmaceuticals ESSA Pharma Elutia Sutro Biopharma Passage Bio (NASDAQ:PASG) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations, risk and community ranking. Does the media refer more to PASG or JMAC? In the previous week, Passage Bio had 5 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 5 mentions for Passage Bio and 0 mentions for Maxpro Capital Acquisition. Maxpro Capital Acquisition's average media sentiment score of 0.00 beat Passage Bio's score of -0.59 indicating that Maxpro Capital Acquisition is being referred to more favorably in the news media. Company Overall Sentiment Passage Bio Negative Maxpro Capital Acquisition Neutral Does the MarketBeat Community prefer PASG or JMAC? Passage Bio received 53 more outperform votes than Maxpro Capital Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformPassage BioOutperform Votes5368.83% Underperform Votes2431.17% Maxpro Capital AcquisitionN/AN/A Do insiders and institutionals have more ownership in PASG or JMAC? 53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. 5.0% of Passage Bio shares are owned by company insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has higher valuation and earnings, PASG or JMAC? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPassage BioN/AN/A-$102.06M-$1.02-0.30Maxpro Capital AcquisitionN/AN/AN/AN/AN/A Which has more volatility and risk, PASG or JMAC? Passage Bio has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Do analysts recommend PASG or JMAC? Passage Bio presently has a consensus target price of $7.50, indicating a potential upside of 2,391.69%. Given Passage Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Passage Bio is more favorable than Maxpro Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Passage Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is PASG or JMAC more profitable? Maxpro Capital Acquisition's return on equity of 0.00% beat Passage Bio's return on equity.Company Net Margins Return on Equity Return on Assets Passage BioN/A -72.53% -52.10% Maxpro Capital Acquisition N/A N/A N/A SummaryPassage Bio beats Maxpro Capital Acquisition on 6 of the 11 factors compared between the two stocks. Get Passage Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PASG vs. The Competition Export to ExcelMetricPassage BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.71M$2.93B$5.37B$8.39BDividend YieldN/A1.72%5.22%4.10%P/E Ratio-0.2630.5026.8419.71Price / SalesN/A400.15392.34117.39Price / CashN/A168.6838.2534.62Price / Book0.153.286.794.50Net Income-$102.06M-$72.17M$3.23B$248.18M7 Day Performance1.21%2.96%1.53%0.20%1 Month Performance-14.00%3.25%10.05%12.37%1 Year Performance-76.11%-28.29%16.71%7.04% Passage Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PASGPassage Bio2.1006 of 5 stars$0.30-4.2%$7.50+2,391.7%-76.5%$18.71MN/A-0.26130JMACMaxpro Capital AcquisitionN/A$5.68flatN/A+1,580.3%$76.27MN/A0.002,021Gap UpINZYInozyme Pharma2.8803 of 5 stars$1.18+2.6%$14.63+1,139.4%-16.0%$76.18MN/A-0.7650Earnings ReportCRBUCaribou Biosciences2.892 of 5 stars$0.82+5.7%$9.33+1,040.9%-67.2%$76.09M$9.99M-0.50100ADAPAdaptimmune Therapeutics2.7359 of 5 stars$0.30+0.9%$1.83+519.9%-74.5%$75.94M$178.03M-1.34490GNTAGenenta Science1.4964 of 5 stars$4.13-5.0%$25.00+506.1%+38.7%$75.45MN/A0.007Gap UpXCURExicure1.4615 of 5 stars$11.86+3.7%N/A+2,082.5%$74.93M$500,000.00-5.7350Gap UpTELOTelomir Pharmaceuticals1.7114 of 5 stars$2.51+0.8%$15.00+497.6%-62.6%$74.71MN/A-4.331News CoverageEPIXESSA Pharma2.0017 of 5 stars$1.68-2.3%$9.50+465.5%-73.2%$74.57MN/A-2.4350News CoveragePositive NewsELUTElutia3.1933 of 5 stars$1.82-12.5%$8.00+339.6%-49.1%$74.14M$24.38M-0.70180Gap DownSTROSutro Biopharma4.3917 of 5 stars$0.87-0.2%$6.63+661.5%-81.5%$73.40M$62.04M-0.54240News CoverageAnalyst ForecastGap Down Related Companies and Tools Related Companies JMAC Alternatives INZY Alternatives CRBU Alternatives ADAP Alternatives GNTA Alternatives XCUR Alternatives TELO Alternatives EPIX Alternatives ELUT Alternatives STRO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PASG) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Passage Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Passage Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PASG Stock Free PASG Stock Alerts